Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QuidelOrtho Corporation

https://www.quidelortho.com/

Latest From QuidelOrtho Corporation

Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Medtech 100 Commercial

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Outlook 2023 Sales & Earnings

NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding

As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.

United Kingdom Cost Effectiveness

Going Early For Maximum Long Term Value From Medtech Deals

Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.

Market Intelligence Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Cytology
    • Molecular Diagnostics & Genetic Testing
    • Therapeutic Drug Monitoring
  • Other Names / Subsidiaries
    • AnDiaTec
    • BioHelix Corporation
    • Diagnostic Hybrids, Inc.
    • Ortho Clinical Diagnostics Inc.
    • Quidel Corporation
UsernamePublicRestriction

Register